Targeted therapies in systemic sclerosis: a narrative review of novel drugs in clinical trials.

IF 4.3 2区医学 Q1 RHEUMATOLOGY

Current opinion in rheumatology Pub Date : 2025-11-01 Epub Date: 2025-08-20 DOI:10.1097/BOR.0000000000001121

Morgan Emokpae, Crystal Cheung, Manvitha Nadella

{"title":"Targeted therapies in systemic sclerosis: a narrative review of novel drugs in clinical trials.","authors":"Morgan Emokpae, Crystal Cheung, Manvitha Nadella","doi":"10.1097/BOR.0000000000001121","DOIUrl":null,"url":null,"abstract":"Purpose of review: Systemic sclerosis (SSc) remains a therapeutic challenge, with conventional immunosuppressive strategies showing inconsistent effects and no disease modifying activity. The lack of head-head trials comparing immunosuppressives with emerging antifibrotic agents further complicates treatment decisions in SSc. This review aims to provide an update on the recent advances in targeted therapies for SSc, with a focus on novel biologics and small molecules that specifically modulate key mechanisms.Recent findings: Advances in molecular profiling have revealed inflammatory and fibrotic endotypes within SSc while imaging studies support a fibroinflammatory subset, highlighting potential therapeutic targets.Summary: A literature search for clinical trials between January 2020 and April 2025 from PubMed/MEDLINE, clinicaltrials.gov, euclinicaltrials.eu databases for targeted therapies in systemic sclerosis revealed a total of 117 clinical trials, of which we described the design, methods and endpoints from 14 studies (2 conference abstracts, 11 trials and 1 case series). These study results offer hope for patients with systemic sclerosis and pave way for future studies directing the development of patient-specific guidelines.","PeriodicalId":11145,"journal":{"name":"Current opinion in rheumatology","volume":" ","pages":"392-403"},"PeriodicalIF":4.3000,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current opinion in rheumatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/BOR.0000000000001121","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/8/20 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"RHEUMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose of review: Systemic sclerosis (SSc) remains a therapeutic challenge, with conventional immunosuppressive strategies showing inconsistent effects and no disease modifying activity. The lack of head-head trials comparing immunosuppressives with emerging antifibrotic agents further complicates treatment decisions in SSc. This review aims to provide an update on the recent advances in targeted therapies for SSc, with a focus on novel biologics and small molecules that specifically modulate key mechanisms.

Recent findings: Advances in molecular profiling have revealed inflammatory and fibrotic endotypes within SSc while imaging studies support a fibroinflammatory subset, highlighting potential therapeutic targets.

Summary: A literature search for clinical trials between January 2020 and April 2025 from PubMed/MEDLINE, clinicaltrials.gov, euclinicaltrials.eu databases for targeted therapies in systemic sclerosis revealed a total of 117 clinical trials, of which we described the design, methods and endpoints from 14 studies (2 conference abstracts, 11 trials and 1 case series). These study results offer hope for patients with systemic sclerosis and pave way for future studies directing the development of patient-specific guidelines.

查看原文本刊更多论文

系统性硬化症的靶向治疗：临床试验新药的叙述性回顾。

综述目的：系统性硬化症（SSc）仍然是一个治疗挑战，传统的免疫抑制策略显示不一致的效果，没有疾病改变活性。缺乏比较免疫抑制剂与新出现的抗纤维化药物的头对头试验，进一步使SSc的治疗决策复杂化。本综述旨在提供SSc靶向治疗的最新进展，重点关注特异性调节关键机制的新型生物制剂和小分子。最新发现：分子谱分析的进展揭示了SSc的炎症和纤维化内型，而成像研究支持纤维炎症亚群，突出了潜在的治疗靶点。摘要：从PubMed/MEDLINE、clinicaltrials.gov、eucclinicaltrials中检索2020年1月至2025年4月的临床试验文献。针对系统性硬化症的靶向治疗的欧盟数据库共显示了117项临床试验，其中我们描述了14项研究的设计、方法和终点（2项会议摘要、11项试验和1个病例系列）。这些研究结果为系统性硬化症患者带来了希望，并为未来的研究铺平了道路，指导制定针对患者的指导方针。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current opinion in rheumatology 医学-风湿病学

CiteScore

9.70

自引率

2.00%

发文量

审稿时长

6-12 weeks

期刊介绍： A high impact review journal which boasts an international readership, Current Opinion in Rheumatology offers a broad-based perspective on the most recent and exciting developments within the field of rheumatology. Published bimonthly, each issue features insightful editorials and high quality invited reviews covering two or three key disciplines which include vasculitis syndromes, medical physiology and rheumatic diseases, crystal deposition diseases and rheumatoid arthritis. Each discipline introduces world renowned guest editors to ensure the journal is at the forefront of knowledge development and delivers balanced, expert assessments of advances from the previous year.